The combined blockade of β-adrenoceptor and COX-2 during the perioperative period to improve long-term cancer outcomes

International Anesthesiology Clinics

Volumn 54, Issue 4, 2016, Pages 72-91

  Ricon, Itay ^a   Hiller, Jonathan G ^b   Ben Eliyahu, Shamgar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ADRENERGIC RECEPTOR; CATECHOLAMINE; PROSTAGLANDIN; PROSTAGLANDIN RECEPTOR BLOCKING AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; HUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME; DISEASE EXACERBATION; INFLAMMATION; METABOLISM; NEOPLASM; PHYSIOLOGICAL STRESS; POSTOPERATIVE COMPLICATION;

ADRENERGIC BETA-ANTAGONISTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATECHOLAMINES; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; NEOPLASMS; PERIOPERATIVE CARE; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; PROSTAGLANDIN ANTAGONISTS; PROSTAGLANDINS; RECEPTORS, ADRENERGIC; STRESS, PHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 84987653174     PISSN: 00205907     EISSN: 15371913     Source Type: Journal    
DOI: 10.1097/AIA.0000000000000116     Document Type: Article

References (114)

1. Neeman E, Ben-Eliyahu S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun. 2013;30:S32-S40.
2. Horowitz M, Neeman E, Sharon E, et al. Exploiting the critical perioperative period to improve long-Term cancer outcomes. Nat Rev Clin Oncol. 2015;12:213-226.
3. Neeman E, Zmora O, Ben-Eliyahu S. A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin Cancer Res. 2012;18:4895-4902.
4. Retsky M, Demicheli R, Hrushesky WJM, et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Curr Med Chem. 2013;20:4163-4176.
5. Hiller J, Brodner G, Gottschalk A. Understanding clinical strategies that may impact tumour growth and metastatic spread at the time of cancer surgery. Best Pract Res Clin Anaesthesiol. 2013;27:427-439.
6. Biki B, Mascha E, Moriarty DC, et al. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. 2008;109: 180-187.
7. Exadaktylos AK, Buggy DJ, Moriarty DC, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis?. Anesthesiology. 2006;105: 660-664.
8. Yamaguchi K, Takagi Y, Aoki S, et al. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg. 2000;232:58-65.
9. Sawabata N, Funaki S, Hyakutake T, et al. Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood?. Surg Today. 2016:1-8. Doi:10.1007/s00595-016-1318-4.
10. Fisher B, Gunduz N, Coyle J, et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice presence of a growth-stimulating removal in mice1 factor in serum following primary tumor. Cancer Res. 1989;48:1996-2001.
11. Abramovitch R, Marikovsky M, Meir G, et al. Stimulation of tumour growth by wound-derived growth factors. Br J Cancer. 1999;79:1392-1398.
12. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
13. Gullino PM. Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. Acta Oncol. 1995;34:439-441.
14. Armaiz-Pena GN, Cole SE, Lutgendorf SK, et al. Neuroendocrine influences on cancer biology. Brain Behav Immun. 2013;30:19-25.
15. Kadosawa T, Watabe A. The effects of surgery-induced immunosuppression and angiogenesis on tumour growth. Vet J. 2015;205:175-179.
16. Bartal I, Melamed R, Greenfeld K, et al. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav Immun. 2010;24:376-386.
17. Greenfeld K, Avraham R, Benish M, et al. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun. 2007;21:503-513.
18. Badwe R, Hawaldar R, Parmar V, et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J Clin Oncol. 2011;29:2845-2851.
19. Byrne K, Levins KJ, Buggy DJ. Can anesthetic-Analgesic technique during primary cancer surgery affect recurrence or metastasis?. Can J Anesth. 2015;63:184-192.
20. Grytli HH, Fagerland MW, Fosså SD, et al. Association between use of b-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2014;65:635-641.
21. Huang XZ, Gao P, Sun JX, et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-Analysis. Cancer Causes Control. 2015;26:589-600.
22. Forget P, Bentin C, Machiels JP, et al. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth. 2014;113:82-87.
23. Cata JP, Kurz A. Challenges in research related to perioperative cancer care and cancer outcomes. Best Pract Res Clin Anaesthesiol. 2013;27:457-464.
24. Cata JP, Villarreal J, Keerty D, et al. Perioperative beta-blocker use and survival in lung cancer patients. J Clin Anesth. 2014;26:106-117.
25. Umar A, Steele VE, Menter DG, et al. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol. 2016;43:65-77.
26. Meron G, Tishler Y, Shaashua L, et al. PGE2 suppresses NK activity in vivo directly and through adrenal hormones: Effects that cannot be reflected by ex vivo assessment of NK cytotoxicity. Brain Behav Immun. 2013;28:128-138.
27. Kim R, Emi M, Tanabe K, et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66:5527-5536.
28. Regulski M, Regulska K, Prukaa W, et al. COX-2 inhibitors: a novel strategy in the management of breast cancer. Drug Discov Today. 2015;21:598-615.
29. Algra AM, Rothwell PM. Effects of regular aspirin on long-Term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518-527.
30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
31. Wu WKK, Yiu Sung JJ, Lee CW, et al. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett. 2010;295:7-16.
32. Wang D, DuBois RN. The role of anti-inflammatory drugs in colorectal cancer. Annu Rev Med. 2013;64:131-144.
33. Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: relevance of prostaglandin e receptors. Biochim Biophys Acta. 2015;1851:414-421.
34. Konya V, Marsche G, Schuligoi R, et al. E-Type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther. 2013;138:485-502.
35. Yokoyama U, Iwatsubo K, Umemura M, et al. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev. 2013;65:1010-1052.
36. Rosenne E, Sorski L, Shaashua L, et al. In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins. Brain Behav Immun. 2014;37:207-219.
37. Yakar I, Melamed R, Shakhar G, et al. Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol. 2003;10:469-479.
38. Sutton L, McGlone E, Lambert K. Do postoperative NSAIDs improve breast cancer outcomes?. A best evidence topic. Int J Surg. 2016;28:173-178.
39. Cardwell CR, Kunzmann AT, Cantwell MM, et al. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. Gastroenterology. 2014;146:700.e2-708.e2.
40. Park JH, McMillan DC, Horgan PG, et al. The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. Cancer Treat Rev. 2014;40:68-77.
41. Rothwell PM, Price JF, Fowkes FGR, et al. Short-Term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602-1612.
42. Rothwell PM, Wilson M, Elwin CE, et al. Long-Term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741-1750.
43. Rothwell PM, Fowkes FGR, Belch JFF, et al. Effect of daily aspirin on long-Term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.
44. Murray LJ, Cooper JA, Hughes CM, et al. Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res. 2014;16:R34.
45. Fraser DM, Sullivan FM, Thompson AM, et al. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014;111: 1-5.
46. Choi JE, Villarreal J, Lasala J, et al. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study. Cancer Med. 2015;4:825-833.
47. Forget P, Berlière M, van Maanen A, et al. Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. Med Hypotheses. 2013;81:707-712.
48. Glasner A, Avraham R, Rosenne E, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a betaadrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol. 2010;184: 2449-2457.
49. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?. Ann Surg Oncol. 2003;10:972-992.
50. Forget P, Machiels JP, Coulie PG, et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol. 2013; 20(suppl 3):S650-S660.
51. Forget P, Vandenhende J, Berliere M, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy?. A retrospective analysis. Anesth Analg. 2010;110:1630-1635.
52. Blouin M, Rhainds M. Use of nonsteroidal anti-inflammatory drugs in colorectal surgery: do the risks cast a shadow on the benefits?. Ann Pharmacother. 2014;48: 1662-1664.
53. Feldheiser A, Aziz O, Baldini G, et al. Enhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice. Acta Anaesthesiol Scand. 2016;60:289-334.
54. Gustafsson UO, Oppelstrup H, Thorell A, et al. Adherence to the ERAS protocol is associated with 5-year survival after colorectal cancer surgery: a retrospective cohort study. World J Surg. 2016;40:1741-1747.
55. Nelson G, Altman AD, Nick A, et al. Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERASs) Society recommendations-part II. Gynecol Oncol. 2016;140:323-332.
56. Lassen K, Coolsen MME, Slim K, et al. Guidelines for perioperative care for pancreaticoduodenectomy: enhanced recovery after surgery (ERAS) society recommendations. World J Surg. 2013;37:240-258.
57. Cerantola Y, Valerio M, Persson B, et al. Guidelines for perioperative care after radical cystectomy for bladder cancer: enhanced recovery after surgery (ERAS) society recommendations. Clin Nutr. 2013;32:879-887.
58. Nagaraja AS, Sadaoui NC, Lutgendorf SK, et al. B-blockers: a new role in cancer chemotherapy?. Expert Opin Investig Drugs. 2013;22:1359-1363.
59. Landmann R. Beta-Adrenergic receptors in human leukocyte subpopulations. Eur J Clin Invest. 1992;22(suppl 1):30-36.
60. Shakhar G, Ben-eliyahu S. In vivo b-Adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. 1998. J Immunol. 1998;160:3251-3258.
61. Melamed R, Rosenne E, Shakhar K, et al. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a b-Adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun. 2005;19:114-126.
62. Benish M, Bartal I, Goldfarb Y, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 2008;15:2042-2052.
63. McCarty MF. A role for cAMP-driven transactivation of EGFR in cancer aggressiveness-Therapeutic implications. Med Hypotheses. 2014;83:142-147.
64. Tang J, Li Z, Lu L, et al. b-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013;23: 533-542.
65. Armaiz-Pena GN, et al. Src activation by b-Adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013;4:1-11.
66. Cole SW, Sood AK. Molecular pathways: beta-Adrenergic signaling in cancer. Clin Cancer Res. 2012;18:1201-1206.
67. Costanzo ES, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. Immunol Allergy Clin North Am. 2011;31:109-132.
68. Nagaraja AS, Dorniak PL, Sadaoui NC, et al. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. 2016;35:2390-2397.
69. Zalli A, Bosch JA, Goodyear O, et al. Targeting-2 adrenergic receptors regulate human T cell function directly and indirectly. Brain Behav Immun. 2015;45:1-8.
70. Priebe HJ. The controversy of peri-operative-blockade: what should I do?. Eur J Vasc Endovasc Surg. 2014;47:119-123.
71. Ben-eliyahu S, Shakhar G, Page G, et al. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and b-Adrenoceptors. Neuroimmunomodulation. 2000;8:154-164.
72. Kim-Fuchs C, Le CP, Pimentel MA, et al. Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-Adrenergic signaling in the pancreatic microenvironment. Brain Behav Immun. 2014;40:40-47.
73. Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29:2635-2644.
74. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29:2645-2652.
75. Watkins JL, Thaker PH, Nick AM, et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015;121: 3444-3451.
76. Cardwell CR, Coleman HG, Murray LJ, et al. Beta-blocker usage and prostate cancer survival: a nested case-control study in the UK Clinical Practice Research Datalink cohort. Cancer Epidemiol. 2014;38:279-285.
77. Heitz F, Du Bois A, Harter P, et al. Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-A combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol. 2013;129:463-466.
78. Lee JW, Shahzad MM, Lin YG, et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009;15:2695-2702.
79. Le CP, Nowell CJ, Kim-Fuchs C, et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nat Commun. 2016;7:1-14.
80. Le CP, Karnezis T, Achen MG, et al. Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches. Best Pract Res Clin Anaesthesiol. 2013;27:409-425.
81. Bhattacharyya GS, Babu KG, Bondarde SA, et al. Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel. ASCO Meet Abstr. 2015;33:302.
82. de la Torre AN, Castaneda I, Hezel AF, et al. Effect of coadministration of propranolol and etodolac (VT-122) plus sorafenib for patients with advanced hepatocellular carcinoma (HCC). ASCO Meet Abstr. 2015;33:390.
83. Zmora O, Shaashua L, Gutman M, et al. The perioperative use of a beta-Adrenergic blocker and a COX-2 inhibitor in colorectal cancer patients for the prevention of cancer recurrence: a preliminary study assessing feasibility and safety. Presented at 23rd Annual PNIRS Scientific Meeting, abstract 1733. Brighton, UK, BBI, 2016. Available at: https://www.pnirs.org/resources/docs/PNIRS%202016%20Program6.pdf.
84. Shaashua L, Shabat-Simon M, Haldar R, et al. Perioperative COX-2 inhibition and beta-Adrenoceptor blockade in breast cancer patients improve markers of immunity and reduce inflammation and primary tumor epithelial-To-mesenchymal transition (EMT) 23rd Annual PNIRS Scientific Meeting. Abstract 1731, Brighton, UK, BBI, 2016. Available at: https://www.pnirs.org/resources/docs/PNIRS%202016%20Abstracts.pdf.
85. Sorski L, Melamed R, Matzner P, et al. Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through b-Adrenoceptors blockade and COX2 inhibition. Brain, Behavior, and Immunity. 2016. (In press).
86. Shaashua L, Satchi-Fainaro R, Sloan E, et al. Surgical Excision of a Primary Tumor Enhances Spontaneous Metastasis of Breast Cancer Through COX-2 and Beta-Adrenergic Pathways. Biology of Cancer: Microenvironment, Metastasis & Therap. NY: Cold Spring Harbor Laboratory; 2015.
87. Inbar S, Neeman E, Avraham R, et al. Do stress responses promote leukemia progression?. an animal study suggesting a role for epinephrine and prostaglandin-e2 through reduced nk activity. PLoS One. 2011;6:1-11.
88. Richard AJ. Etodolac (Lodines): profile of an established selective COX-2 inhibitor. Inflammopharmacology. 2001;9:63-70.
89. Propranolol label and approval history. 2003. Available at: http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed April 1, 2016.
90. Benjamin B, Hazut O, Shaashua L, et al. Effect of beta blocker combined with COX-2 inhibitor on colonic anastomosis in rats. Int J Colorectal Dis. 2010;25:1459-1464.
91. Hazut O, Shaashua L, Benish M, et al. The effect of b-Adrenergic blockade and COX-2 inhibition on healing of colon, muscle, and skin in rats undergoing colonic anastomosis. Int J Clin Pharmacol Ther. 2011;49:545-554.
92. Mathias RA, Gopal SK, Simpson RJ. Contribution of cells undergoing epithelialmesenchymal transition to the tumour microenvironment. J Proteomics. 2013;78: 545-557.
93. Tiwari N, Gheldof A, Tatari M, et al. Seminars in Cancer Biology EMTas the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 2012;22:194-207.
94. Al-Sukaini A, Hart C, Robinson R, et al. Abstract 4350: prognostic potential of epithelial to mesenchymal transition in prostate cancer at first presentation. Cancer Res. 2015;75:4350-4350.
95. Ash SA, Buggy DJ. Does regional anaesthesia and analgesia or opioid analgesia influence recurrence after primary cancer surgery?. An update of available evidence. Best Pract Res Clin Anaesthesiol. 2013;27:441-456.
96. de Oliveira GS, Ahmad S, Schink JC, et al. Intraoperative neuraxial anesthesia but not postoperative neuraxial analgesia is associated with increased relapse-free survival in ovarian cancer patients after primary cytoreductive surgery. Reg Anesth Pain Med. 2011;36:271-277.
97. Hiller JG, Hacking MB, Link EK, et al. Perioperative epidural analgesia reduces cancer recurrence after gastro-oesophageal surgery. Acta Anaesthesiol Scand. 2014;58: 281-290.
98. Cummings KC 3rd, Xu F, Cummings LC, et al. A comparison of epidural analgesia and traditional pain management effects on survival and cancer recurrence after colectomy: a population-based study. Anesthesiology. 2012;116:797-806.
99. Ismail H, Ho KM, Narayan K, et al. S. Effect of neuraxial anaesthesia on tumour progression in cervical cancer patients treated with brachytherapy: a retrospective cohort study. Br J Anaesth. 2010;105:145-149.
100. Myles PS, Peyton P, Silbert B, et al. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ. 2011;342:d1491.
101. Lacassie HJ, Cartagena J, Brañes J, et al. The relationship between neuraxial anesthesia and advanced ovarian cancer-related outcomes in the chilean population. Anesth Analg. 2013;117:653-660.
102. Roiss M, Schiffmann J, Tennstedt P, et al. Oncological long-Term outcome of 4772 patients with prostate cancer undergoing radical prostatectomy: does the anaesthetic technique matter?. Eur J Surg Oncol. 2014;40:1686-1692.
103. Cata JP, Gottumukkala V, Thakar D, et al. Effects of postoperative epidural analgesia on recurrence-free and overall survival in patients with nonsmall cell lung cancer. J Clin Anesth. 2014;26:3-17.
104. Group PS. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371: 1839-1847.
105. Ashes C, Judelman S. Selective b1-Antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolola single-center cohort study of 44, 092. Anesthesiology. 2013;119:777-787.
106. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e77-e137.
107. Kristensen SD, Knuuti J. New ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J. 2014;35:2344-2345.
108. Wattchow DA, De Fontgalland D, Bampton PA, et al. Clinical trial: the impact of cyclooxygenase inhibitors on gastrointestinal recovery after major surgery-A randomized double blind controlled trial of celecoxib or diclofenac vs. placebo. Aliment Pharmacol Ther. 2009;30:987-998.
109. Cheung R, Krishnaswami S, Kowalski K. Analgesic efficacy of celecoxib in postoperative oral surgery active-And placebo-controlled study. Clin Ther. 2007;29: 2498-2510.
110. Huang M, Chen Z, Wei B, et al. Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. Acta Pharmacol Sin. 2007;28:1842-1850.
111. Lee YS, Kim H, Brahim JS, et al. Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain. 2007;129:279-286.
112. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. Meta-Analysis of randomised trials. BMJ. 2006;332:1302-1308.
113. FDA Drug Safety Communication: FDA strengthens warning that non-Aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes.2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm. Accessed April 1, 2016.
114. Wojtowicz ME, Dunn BK, Umar A. Immunologic approaches to cancer prevention-current status, challenges, and future perspectives. Semin Oncol. 2016; 43:161-172.